via Carnegie Mellon University
Carnegie Mellon University researchers reveal fastest known COVID-19 antibody test with high sensitivity due to a unique, 3D printing technology and an electrochemical reaction.
Researchers at Carnegie Mellon University, in collaboration with the University of Pittsburgh and UPMC, have developed one of the fastest known COVID-19 antibody tests. The test results are available in 10 to 15 seconds and detect the presence of two of the antibodies to SARS-CoV-2, the virus responsible for COVID-19. Such a quick and effective test could be a game-changer for controlling the spread of the pandemic.
The breakthrough test would require a very small drop of blood from a fingertip (less than five microliters) to identify two antibodies of the virus: spike S1 protein and receptor binding domain (RBD). It can detect antibody concentrations at an extremely low level, one picomolar (0.15 nanograms per milliliter), through an electrochemical reaction within a handheld microfluidic device. Results are sent almost immediately to a simple interface on a smart phone. The device can be cleaned (i.e. regenerated) within one minute using a special chemistry discovered by the researchers that allows multiple, successive readings from the same device.
A simple yet elegant additive manufacturing technology called aerosol jet 3D printing is responsible for the efficiency and accuracy of this testing device. Tiny, inexpensive gold micropillar electrodes are printed at nanoscale using aerosol droplets that are thermally sintered together. This causes a rough, irregular surface that provides increased surface area of the micropillars and an enhanced electrochemical reaction, where antibodies can latch on to antigens coated on the electrode. The specific geometry allows the micropillars to load more proteins for detection, resulting in very accurate, quick results.
“This sensing platform can also be used to detect other infectious diseases, potentially affecting the course of pandemics.”
RAHUL PANAT, ASSOCIATE PROFESSOR, DEPARTMENT OF MECHANICAL ENGINEERING
The test has a very low error rate since the binding reaction between the antibody and antigen used in the device is highly selective. This natural design was exploited by the researchers to their advantage.
The device, which has a provisional patent, is inexpensive to make (in the tens of dollars). And, the manufacturing capabilities already exist.
“My research team was working on 3D printed high-performance sensors to detect dopamine, a chemical in brain, when we realized that we could adapt our work for COVID-19 testing,” said?Rahul Panat, an associate professor of mechanical engineering at Carnegie Mellon who uses specialized additive manufacturing techniques for research ranging from brain-computer interfaces to biomonitoring devices. “We shifted our research to apply our expertise to combatting this devastating pandemic.”
Knowing the work would require a multidisciplinary approach, Panat collaborated with Shou-Jiang Gao, leader of the Cancer Virology Program at UPMC Hillman Cancer Center and professor of microbiology and molecular genetics at the University of Pittsburgh. Azahar Ali, a postdoctoral researcher in Panat’s Advanced Manufacturing and Materials Lab, was the lead author of the study. Their research findings are available on MedRxiv in anticipation of peer review.
“We’re sharing these results at the time of preprint and prior to peer review because of the significant, potential impact on public health,” said Panat.
This sensing platform can also be used for the detection of other infectious diseases.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
COVID-19 Antibody Test
- Needle-free jet injection of novel COVID-19 DNA vaccine shows promise in animal model
In a recent study posted to the bioRxiv* server, researchers at the United States Army Medical Research Institute of Infectious Diseases evaluated the immunogenicity of a severe acute respiratory ...
- WHO 'strongly advises against' use of antibody therapies as COVID treatment
The World Health Organization (WHO) has flipped its position on antibody therapies to treat COVID as they believe the Omicron variant's latest offshoots have rendered them obsolete.
- WHO strongly advises against two antibody therapies for Covid-19
Mounting evidence from lab tests suggests the two therapies have limited clinical activity against the latest iterations of the coronavirus ...
- WHO 'strongly advises against' use of two COVID-19 antibody therapies: BMJ
The WHO Guideline Development Group of international experts noted that antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19.
- WHO renders two Covid-19 antibody therapies 'obsolete'
Two Covid-19 antibody therapies are no longer recommended by the World Health Organization, on the basis that Omicron and the variant's latest offshoots have likely rendered them obsolete.
Go deeper with Google Headlines on:
COVID-19 Antibody Test
Go deeper with Bing News on:
- Joe Biden says the COVID-19 pandemic is over. This is what the data tells us
President Joe Biden said in a 60 Minutes interview Sunday that the COVID-19 pandemic is a thing of the past. "The pandemic is over," he said. "We still have a problem with COVID. We're still doing a ...
- State health department is not reporting COVID-19 reinfections
Iowa does not include subsequent COVID-19 infections of the same person in the number of newly confirmed cases it reports to federal health officials or in the weekly case updates on its website, even ...
- New test to predict patient's risk of developing severe Covid-19: What study says
The CovGENE test reportedly analyses genes expressed in a person's blood to determine whether they may experience a severe disease course with increased risk of death ...
- Novel test can identify patients at risk of severe COVID-19
Scientists in the US have developed a new genomic test that can predict a patient's risk of developing severe COVID-19, an advance that could help doctors quickly begin tailored treatment. The test ...
- New genomic test can predict a patient's risk of developing severe COVID-19, resaerch suggests
A genomic test being developed by a Charlottesville, Va., company can predict a patient's risk of developing severe COVID-19, new research from UVA Health suggests.